The checkpoint immunotherapy revolution: What started as a trickle has become a flood, despite some daunting adverse effects, new drugs, indications, and combinations continue to emerge

P and T

Volumn 41, Issue 3, 2016, Pages 185-191

  Alexander, Walter ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; B RAF KINASE; BEVACIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DOCETAXEL; EPACADOSTAT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; NIVOLUMAB; PAZOPANIB; PEMBROLIZUMAB; PV 10; SUNITINIB; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; DRUG APPROVAL; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LONG TERM SURVIVAL; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 84962013859     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363, (8):711-723.10.1056/NEJMoa1003466 [Epublication ahead of print, June 5, 2010].
2. Food and Drug Administration. FDA approves new treatment for a type of late-stage skin cancer. March 25 2011, Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm1193237.htm. Accessed February 3, 2016.
3. Food and Drug Administration. FDA approves Yervoy to reduce the risk of melanoma returning after surgery. October 28 2015, Available at: www.fda.gov/NewsEvents/Newsroom/Press-Announcements/ucm469944.htm. Accessed February 3, 2016.
4. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. Presentation at 2014 American Society of Clinical Oncology Annual MeetingChicago, IllinoisJune 2, 2014Abstract published in J Clin Oncol 2014, 32:5s(suppl):LBA9008.
5. Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014, 21, (2):371-381.10.1530/ERC-13-0499
6. Merck. Merck to present new data in five tumor types from studies evaluating pembrolizumab, the company’s investigational anti-PD-1 antibody, at ESMO 2014. September 2, 2014. Available at: www.mercknewsroom.com/news-release/oncology-newsroom/merck-present-new-data-five-tumor-types-studies-evaluating-pembrolizu. Accessed February 3, 2016.
7. Food and Drug Administration. FDA approves Keytruda for advanced melanoma. September 4 2014, Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm. Accessed February 3, 2016.
8. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384, (9948):1109-1117.10.1016/S0140-6736(14)60958-2
9. Keytruda (pembrolizumab) prescribing information Whitehouse Station, New Jersey: Merck. December 2015, Available at: www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed February 3, 2016.
10. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372, (4):320-330.10.1056/NEJMoa1412082
11. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015, 372, (4):311-319. 10.1056/NEJMoa1411087 [Epublication ahead of print, December 6, 2014]
12. Food and Drug Administration. FDA approves Opdivo for advanced melanoma. December 22 2014, Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm. Accessed February 3, 2016.
13. Food and Drug Administration. FDA expands approved use of Opdivo to treat lung cancer. March 4 2015, Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm. Accessed February 3, 2016.
14. Food and Drug Administration. Nivolumab in combination with ipilimumab. October 12015, Available at: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm. Accessed February 3, 2016.
15. Food and Drug Administration. FDA approves Keytruda for advanced non-small cell lung cancer. October 22015, Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm. Accessed February 3, 2016.
16. Food and Drug Administration. FDA expands approved use of Opdivo in advanced lung cancer. October 92015, Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm. Accessed February 3, 2016.
17. Food and Drug Administration. FDA approves Opdivo to treat advanced form of kidney cancer. November 232015, Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm. Accessed February 3, 2016.
18. Merck. FDA approves expanded indication for Merck’s Keytruda (pembrolizumab) for the treatment of patients with advanced melanoma. December 18, 2015. Available at: www.businesswire.com/news/home/20151218005982/en/FDA-Approves-Expanded-Indication-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab. Accessed February 3, 2016.
19. Bristol-Myers Squibb. Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) regimen receives expanded FDA approval in unresectable or metastatic melanoma across BRAF status. January 232016, Available at: http://news.bms.com/press-release/bmy/bristol-myers-squibbs-opdivo-nivolumab-yervoy-ipilimumab-regimen-receives-expanded. Accessed February 3, 2016.
20. Curtis BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013, 73, (24):7189-7198.10.1158/0008-5472.CAN-12-4174
21. Kudchadkar RR, Gibney GT, Weber J, et al. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. Presentation at 2013 American Society of Clinical OncologyChicago, IllinoisMay 31 to June 4, 2013Abstract published in J Clin Oncol 2013, 31(suppl): 9079.
22. Society for the Immunotherapy of Cancer. Preliminary results from phase I/II study of epacadostat in combination with pembrolizumab demonstrates 53% overall response rate across a number of cancer types. November 62015, Available at: www.sitcancer.org/about-sitc/newsroom/press-releases/epacadostat-in-combination-with-pembrolizumab-presented-at-sitc-2015. Accessed February 1, 2016.
23. Nemunaitis JJ, Andtbacka RH, Ross M, et al. Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIB-IV melanoma. Poster presentation at European Society for Medical Oncology 2014Madrid, SpainSeptember 28, 2014Abstract published in Ann Oncol 2014, 25(suppl 4):iv374-iv393.
24. Promising strategy for advanced melanoma: intralesional therapies plus systemic immunotherapies. Cancer Watch 2014, 23, (12):186-187.
25. Amgen. FDA approves Imlygic (talimogene laherparepvec) as first oncolytic viral therapy in the U.S. October 27, 2015. Available at: www.amgen.com/media/news-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us. Accessed February 3, 2016.
26. Pilon-Thomas SA, Weber A, Kodumudi K, et al. Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine models of breast cancer and melanoma. Presentation at American Association for Cancer Research 104th Annual MeetingWashington, DCApril 6 to 10, 2013Abstract published in Cancer Res 2013, 73:1248.
27. Sarnaik A, Crago G, Liu H, et al. Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions. Presentation at 2014 American Society of Clinical Oncology Annual MeetingChicago, IllinoisMay 30 to June 3, 2014Abstract published in J Clin Oncol 2014, 32:5s (suppl):9028.
28. PV-10 in advanced melanoma: high response rates, evidence of systemic response. Cancer Watch 2013, 22, (10):155-156.
29. Alexander W. Society for Melanoma Research and American Heart Association Scientific Sessions. P T 2015, 40, (1):68-72.
30. Andtbacka RHI, Chastain M, Li A, et al. Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL). Poster presentation at 2015 American Society of Clinical Oncology Annual MeetingChicago, IllinoisMay 29 to June 2, 2015Abstract published in J Clin Oncol 2015, 33(suppl):TPS9094.
31. Herbst RS, Baas P, Kim DW. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Published online December 19, 2015. Available at: http://dx.doi.org/10.1016/S0140-6736(15)01281-7. Accessed February 1, 2016.
32. Hammers HJ, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma. Presentation at 2014 American Society of Clinical Oncology Annual MeetingChicago, IllinoisMay 30 to June 3, 2014Abstract published in J Clin Oncol 2014, 32(suppl): 4504.